Michael R Liebowitz 1 , Gregory Asnis , Richard Mangano , Evan Tzanis . Show Affiliations »
Abstract
Show RCT »
Hide RCT «
OBJECTIVE: To evaluate the efficacy, safety, and tolerability of venlafaxine extended release (ER ) in short-term treatment of panic disorder . METHOD: In this multicenter, double-blind study, conducted from April 2001 to December 2002, 343 adult outpatients who met criteria for panic disorder (with and without agoraphobia ) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, were randomly assigned to flexible-dose venlafaxine ER (75-225 mg/d) or placebo for 10 weeks (N = 155 per group, intent-to-treat population). The primary outcome measure was the percentage of panic-free patients as assessed using the Sheehan Panic and Anticipatory Anxiety Scale . Key secondary measures included the Panic Disorder Severity Scale (PDSS) score and Clinical Global Impressions-Improvement (CGI-I) scale response (score = 1 or 2 ). Last-observation-carried-forward data were analyzed, and statistical significance was set at p <or= .05. RESULTS: At week 10, the percentage of patients who were free from full-symptom panic attacks was 52% in the venlafaxine ER group and 43% in the placebo group (p = .11). Mean change from baseline in PDSS total score was significantly (p = .006) greater for the venlafaxine ER group (-9.3) than for the placebo group (-7.5), and significantly (p = .03) more venlafaxine ER -treated patients achieved CGI -I response (71%) than did those receiving placebo (59%) at week 10. Treatment with venlafaxine ER was generally safe and well tolerated . Adverse events were the primary or secondary cause for discontinuation for 7 placebo patients (4%) and 12 venlafaxine ER patients (7%). CONCLUSIONS: Venlafaxine ER appears to be effective, safe, and well tolerated in short-term treatment of panic disorder , although the results fell just short of significance on the primary outcome measure. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00038896. ©Copyright 2009 Physicians Postgraduate Press, Inc.
RCT Entities: Population
Interventions
Outcomes
OBJECTIVE: To evaluate the efficacy, safety, and tolerability of venlafaxine extended release (ER) in short-term treatment of panic disorder . METHOD: In this multicenter, double-blind study, conducted from April 2001 to December 2002, 343 adult outpatients who met criteria for panic disorder (with and without agoraphobia ) according to the Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition, were randomly assigned to flexible-dose venlafaxine ER (75-225 mg/d) or placebo for 10 weeks (N = 155 per group, intent-to-treat population). The primary outcome measure was the percentage of panic-free patients as assessed using the Sheehan Panic and Anticipatory Anxiety Scale. Key secondary measures included the Panic Disorder Severity Scale (PDSS) score and Clinical Global Impressions-Improvement (CGI-I) scale response (score = 1 or 2). Last-observation-carried-forward data were analyzed, and statistical significance was set at p <or= .05. RESULTS: At week 10, the percentage of patients who were free from full-symptom panic attacks was 52% in the venlafaxine ER group and 43% in the placebo group (p = .11). Mean change from baseline in PDSS total score was significantly (p = .006) greater for the venlafaxine ER group (-9.3) than for the placebo group (-7.5), and significantly (p = .03) more venlafaxine ER -treated patients achieved CGI-I response (71%) than did those receiving placebo (59%) at week 10. Treatment with venlafaxine ER was generally safe and well tolerated. Adverse events were the primary or secondary cause for discontinuation for 7 placebo patients (4%) and 12 venlafaxine ER patients (7%). CONCLUSIONS: Venlafaxine ER appears to be effective, safe, and well tolerated in short-term treatment of panic disorder , although the results fell just short of significance on the primary outcome measure. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00038896. ©Copyright 2009 Physicians Postgraduate Press, Inc.
Entities: Chemical
Disease
Species
Mesh: See more »
Substances: See more »
Year: 2009
PMID: 19358784 DOI: 10.4088/jcp.08m04238
Source DB: PubMed Journal: J Clin Psychiatry ISSN: 0160-6689 Impact factor: 4.384